Leerink Swann Reiterates an 'Outperform' on Jazz Pharmaceuticals (JAZZ); Xyrem Patent Strengthens
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $108.83 --0%
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 9 | New: 13
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 9 | New: 13
Join SI Premium – FREE
Leerink Swann reiterates an 'Outperform' on Jazz Pharmaceuticals (NASDAQ: JAZZ) price target of $70.00.
Analyst, Michael Schmidt, said, "JAZZ today announced that a new patent related to Xyrem titled "Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy" will issue today. The new patent, number 8,262,650, will be submitted for listing in the FDA's Orange Book. We believe this is a positive for JAZZ since this newly issued patent and several other patent applications for Xyrem, which are currently in various stages under revision by the US PTO, may strengthen JAZZ's IP position over the 8 patents subject to litigation with Roxane."
Schmidt also sees continued flexibility in JAZZ's management, especially after the divestiture of its women's health business. More acquisitions to help revenues and profitability should warrant higher multiples as well.
For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.
Shares of Jazz Pharmaceuticals closed at $43.56 yesterday.
Analyst, Michael Schmidt, said, "JAZZ today announced that a new patent related to Xyrem titled "Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy" will issue today. The new patent, number 8,262,650, will be submitted for listing in the FDA's Orange Book. We believe this is a positive for JAZZ since this newly issued patent and several other patent applications for Xyrem, which are currently in various stages under revision by the US PTO, may strengthen JAZZ's IP position over the 8 patents subject to litigation with Roxane."
Schmidt also sees continued flexibility in JAZZ's management, especially after the divestiture of its women's health business. More acquisitions to help revenues and profitability should warrant higher multiples as well.
For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.
Shares of Jazz Pharmaceuticals closed at $43.56 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Northwest Bancshares, Inc. (NWBI) PT Lowered to $10 at Piper Sandler
- William Blair Starts First Advantage (FA) at Outperform, 'Best-in-Class Background Screener'
- United Microelectronics Corp (2303:TT) (UMC) PT Lowered to NT$47 at HSBC
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
